Qiagen

QIAGEN Builds on Leading Position in Precision Medicine With Novel Solutions in Oncology

Thursday, May 28, 2020 - 9:05pm

QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of novel solutions enabling faster, better analysis of genomic variations in cancer accelerating multiple applications of Precision Medicine.

Key Points: 
  • QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of novel solutions enabling faster, better analysis of genomic variations in cancer accelerating multiple applications of Precision Medicine.
  • QIAGEN is showcasing its broad portfolio of Sample to Insight solutions for cancer in connection with the 2020 American Society of Clinical Oncology (ASCO) Annual Meeting, being held virtually from May 29-31.
  • While we serve the worlds needs for testing tools in the COVID-19 pandemic, QIAGEN also continues to deliver cutting-edge molecular solutions for cancer research and improving patient outcomes.
  • They create true Sample to Insight solutions for a variety of oncology research applications.

Coronavirus Test Kits Market Segmented by Government and Non-Government End-Users with Regional Analysis

Wednesday, May 27, 2020 - 4:00pm

The coronavirus testing kits market covers the following areas:

Key Points: 
  • The coronavirus testing kits market covers the following areas:
    The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading coronavirus testing kits market vendors that include Abbott Laboratories, BGI Genomics Co. Ltd., Danaher Corp., F. Hoffmann-La Roche Ltd., Hologic Inc., Laboratory Corp. of America Holdings, QIAGEN GmbH, Seegene Inc., SolGent Co. Ltd., and Thermo Fisher Scientific Inc. Also, the coronavirus testing kits market analysis report includes information on upcoming trends and challenges that will influence market growth.
  • The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry.
  • The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
  • This market research report provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast an accurate market growth.

Global Bioinformatics Industry Analysis, 2014-2024 Featuring Profiles of Leading Players Including Illumina, Life Technologies, Qiagen, Agilent Technologies, and PerkinElmer

Tuesday, May 19, 2020 - 2:15pm

The Global Bioinformatics Market is anticipated to grow at a CAGR of close to 18% during the forecast period, reaching a market value of approximately $14 billion by 2024.

Key Points: 
  • The Global Bioinformatics Market is anticipated to grow at a CAGR of close to 18% during the forecast period, reaching a market value of approximately $14 billion by 2024.
  • The factors responsible for the growth of the bioinformatics market includes rise in nucleic acid and protein sequencing and increasing initiatives from the government and private organizations.
  • The Global Bioinformatics Market can be segmented based on product & services, applications, sectors and regional analysis.
  • The major players operating in the Global Bioinformatics Market include Illumina Inc. Life Technologies (Thermo Fischer Scientific), Qiagen NV, Agilent Technologies, PerkinElmer, Accelrys Inc., Geneva Bioinformatics SA, Ontoforce, Data4Cure and Life Map Sciences (Biotime).

Global Molecular Diagnostics Markets, Forecast to 2029: Technologies, Applications, Regulations and Companies - ResearchAndMarkets.com

Tuesday, May 19, 2020 - 12:16pm

The "Molecular Diagnostics - Technologies, Markets and Companies" report from Jain PharmaBiotech has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Molecular Diagnostics - Technologies, Markets and Companies" report from Jain PharmaBiotech has been added to ResearchAndMarkets.com's offering.
  • The most comprehensive and up-to-date one-stop source of information on technical and commercial aspects of molecular diagnostics.
  • The number of companies involved in molecular diagnostics has increased remarkably during the past few years.
  • A new edition in 1997 "Molecular Diagnostics I" as well as the next edition, "Molecular Diagnostics II" in 1999, were published by Decision Resources Inc, USA.

QIAGEN Announces Publication of Reasoned Position Statement for Proposed Acquisition by Thermo Fisher and Date for Annual General Meeting

Monday, May 18, 2020 - 8:18am

The Offer Document relates to the recommended offer by Thermo Fisher to fully acquire all issued shares in QIAGEN as announced on March 3, 2020.

Key Points: 
  • The Offer Document relates to the recommended offer by Thermo Fisher to fully acquire all issued shares in QIAGEN as announced on March 3, 2020.
  • QIAGEN has published the Joint Reasoned Position Statement of the Managing Board and the Supervisory Board in accordance with Section 27 para.
  • Additionally, QIAGEN announced that the Annual General Meeting of Shareholders (AGM) is planned to be held on June 30, 2020, at 15:00 CEST.
  • In addition, Thermo Fishers tender offer statement and other documents it files with the SEC are available at https://ir.thermofisher.com/investors .

Analysis on Impact of COVID-19 - Helicobacter Pylori Diagnostics Market 2020-2024 | Resistance of H. Pylori to Antibiotics to Boost Growth | Technavio

Thursday, May 14, 2020 - 10:00am

Our helicobacter pylori diagnostics market report covers the following areas:

Key Points: 
  • Our helicobacter pylori diagnostics market report covers the following areas:
    This study identifies growing shift toward direct-to-consumer testing as one of the prime reasons driving the helicobacter pylori diagnostics market growth during the next few years.
  • Helicobacter Pylori Diagnostics Market 2020-2024: Vendor Analysis
    We provide a detailed analysis of vendors operating in the helicobacter pylori diagnostics market, including some of the vendors such as Abbott Laboratories, Becton, Dickinson and Co., bioMrieux SA, Bio-Rad Laboratories Inc., Cardinal Health Inc., F. Hoffmann-La Roche Ltd., Omega Diagnostics Group Plc, QIAGEN N.V., Quest Diagnostics Inc., and Thermo Fisher Scientific Inc.
  • Backed with competitive intelligence and benchmarking, our research reports on the helicobacter pylori diagnostics market are designed to provide entry support, customer profile and M&As as well as go-to-market strategy support.
  • Helicobacter Pylori Diagnostics Market 2020-2024: Key Highlights

QIAGEN Reports Full Results for First Quarter of 2020

Wednesday, May 6, 2020 - 9:05pm

QIAGEN N.V. (NYSE:QGEN; Frankfurt Prime Standard:QIA) announced full results of operations for the first quarter of 2020, with net sales and adjusted earnings per share (EPS) in line with the preliminary results announced on April 9, 2020.

Key Points: 
  • QIAGEN N.V. (NYSE:QGEN; Frankfurt Prime Standard:QIA) announced full results of operations for the first quarter of 2020, with net sales and adjusted earnings per share (EPS) in line with the preliminary results announced on April 9, 2020.
  • Net sales grew 7% (+9% at constant exchange rates, or CER) and adjusted earnings per share were $0.34 CER.
  • QIAGEN employees around the world are fully mobilized to address the significant demand for testing solutions needed in the global response to the coronavirus pandemic.
  • Based on trends to date, we expect ongoing strong growth for the second quarter of 2020 in both sales and adjusted earnings per share.

QIAGEN Expects Higher Results for Q2 2020 Based on Trends to Date and Suspends Outlook for Full-Year 2020

Tuesday, May 5, 2020 - 9:55pm

The possible consequences on QIAGENs production, supply chains and long-term demand cannot be reliably gauged.

Key Points: 
  • The possible consequences on QIAGENs production, supply chains and long-term demand cannot be reliably gauged.
  • Consequently, QIAGEN has decided to suspend its outlook for the full-year 2020 at this time.
  • QIAGEN provides solutions to more than 500,000 customers around the world in Molecular Diagnostics (human healthcare) and Life Sciences (academia, pharma R&D and industrial applications, primarily forensics).
  • As of March 31, 2020, QIAGEN employed approximately 5,100 people in over 35 locations worldwide.

Global Nucleic Acid Isolation and Purification Industry, 2020-2029 - Detailed Company Profiles of 22 Key Players, Interviews with KOLs of 20 Leading & Emerging Companies

Tuesday, May 5, 2020 - 1:00pm

Nucleic acid isolation and purification market for kits is expected to witness a robust CAGR of 6.25% during the forecast period 2020-2029.

Key Points: 
  • Nucleic acid isolation and purification market for kits is expected to witness a robust CAGR of 6.25% during the forecast period 2020-2029.
  • ThermoFisher Scientific Inc. is currently the largest shareholder in the global nucleic acid isolation and purification market for instruments.
  • QIAGEN N.V., is currently the largest shareholder in the global nucleic acid isolation and purification market for consumables.
  • What are the major market drivers, challenges, and opportunities in the global nucleic acid isolation and purification market?

2020 Insights on the Global Infectious Disease Molecular Diagnostics Market - Business and Technological Trends in Major Markets - ResearchAndMarkets.com

Tuesday, May 5, 2020 - 12:20pm

This new seven-country study contains is designed to help current suppliers and potential market entrants identify and evaluate emerging opportunities in the infectious disease molecular diagnostics market during the next five years.

Key Points: 
  • This new seven-country study contains is designed to help current suppliers and potential market entrants identify and evaluate emerging opportunities in the infectious disease molecular diagnostics market during the next five years.
  • Specific product and business opportunities for instrument and consumable suppliers.
  • The infectious disease molecular diagnostics market is one of the most rapidly growing segment of the in vitro diagnostics industry.
  • In order to successfully capitalize on the opportunities presented by the infectious disease molecular diagnostics market, many companies are already exploiting new molecular technologies as corporate strategic assets, managed in support of business and marketing strategies.